ProCE Banner Activity

My Take on Viral Hepatitis Treatment Advances From EASL 2022

Clinical Thought
Read my take on which new viral hepatitis data from EASL 2022 are the most practice changing, including HBV novel therapeutics in development, therapeutic vaccination for HBV cure, emerging treatments for HDV, HCV care cascade, and the need for HCC monitoring post HCV cure.

Released: July 13, 2022

Expiration: July 12, 2023

No longer available for credit.

Share

Faculty

Nancy Reau

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Nancy Reau, MD: consultant: AbbVie, Arbutus, Gilead Sciences, Intercept, Salix; researcher (paid to her institution): AbbVie, Gilead Sciences.